We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Hypofractionated Versus Standard Fractionated Whole Breast Irradiation to Node-negative Breast Cancer Patients

This study is ongoing, but not recruiting participants.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00909818
First Posted: May 29, 2009
Last Update Posted: August 1, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborator:
Danish Cancer Society
Information provided by (Responsible Party):
Birgitte Offersen, Danish Breast Cancer Cooperative Group
  Purpose
The purpose of this study is to investigate the difference in late radiation morbidity between hypofractionated and standard fractionated breast irradiation given to women operated with breast conservation for early breast cancer.

Condition Intervention
Breast Cancer Carcinoma in Situ of the Breast Radiation: standard fractionated radiotherapy Radiation: hypofractionated radiotherapy

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Hypofractionated Versus Standard Fractionated Whole Breast Irradiation to Node-negative Breast Cancer Patients: a Randomized Phase II Trial, CIRRO (The Lundbeck Foundation Center for International Research in Radiation Oncology)

Resource links provided by NLM:


Further study details as provided by Birgitte Offersen, Danish Breast Cancer Cooperative Group:

Primary Outcome Measures:
  • Grade 2 or 3 fibrosis 3 years after radiotherapy [ Time Frame: 3 years ]

Secondary Outcome Measures:
  • Any other late morbidity after adjuvant radiotherapy, genetic risk profile for late morbidity, recurrence/survival [ Time Frame: 10 years ]

Estimated Enrollment: 976
Study Start Date: May 2009
Estimated Study Completion Date: May 2022
Estimated Primary Completion Date: May 2022 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: standard fractionated radiotherapy
50 Gy/25 fractions, 2.00 Gy/fraction, 5 fractions per week
Radiation: standard fractionated radiotherapy
standard fractionated radiotherapy 50 Gy/25 fractions
Experimental: hypofractionated radiotherapy
hypofractionated radiotherapy 40 Gy/15 fractions
Radiation: hypofractionated radiotherapy
hypofractionated radiotherapy 40 Gy/15 fractions

Detailed Description:

The randomization is between 50 Gy/25 fractions, 2.0 Gy per fraction, 5 fractions weekly, and 40 Gy/15 fractions, 2.67 Gy per fraction, 5 fractions weekly. The primary endpoint is late radiation morbidity; secondly, we want to investigate the frequency of local recurrences, and try to establish a genetic risk profile for development of late radiation morbidity.

The hypothesis is that women operated with breast conserving strategy for early breast cancer can be offered moderately hypofractionated radiotherapy without developing more late radiation morbidity compared to standard fractionated radiotherapy.

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   41 Years and older   (Adult, Senior)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • operated with breast conserving strategy for:

    1. invasive breast cancer, pT1-2, pN0-1mi, M0 OR
    2. carcinoma in situ of the breast

Exclusion Criteria:

  • previous radiation of the breast/thorax
  • breast implants
  • pregnant/lactating
  • comorbidity which may hinder the patient in completing the therapy and complete follow up for 10 years
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00909818


Locations
Denmark
The Danish Breast Cancer Cooperative Group
Copenhagen, Denmark, DK-2100 Ø
Sponsors and Collaborators
Danish Breast Cancer Cooperative Group
Danish Cancer Society
Investigators
Study Chair: Lars Stenbygaard, MD Aalborg Universitetshospital
Study Chair: Birgitte Offersen, MD, Ph.D Aarhus University Hospital
Study Chair: Erik Jakobsen, MD Vejle Hospital
Study Chair: Mette H Nielsen, MD, phd Odense University Hospital
Principal Investigator: Birgitte Offersen, MD, phd Aarhus University Hospital
Study Chair: Mechthild Krause, M.D., Prof University Clinic Carl Gustav Carus Dresden
Study Chair: Andreas Schreiber, M.D., Ph.D. Praxis für Strahlentherapie am Klinikum Dresden-Friedrichstadt
Study Chair: Ingvil Mjaaland, M.D. Helse Stavanger HF, Sorlandet Sykehus HF
Study Chair: Unn-Miriam Kasti, M.D. Kristiansand Sykehus
  More Information

Responsible Party: Birgitte Offersen, M.D., ph.d., associate professor, Danish Breast Cancer Cooperative Group
ClinicalTrials.gov Identifier: NCT00909818     History of Changes
Other Study ID Numbers: DBCG hypo protocol
CIRRO IP030209
The Danish Cancer Society
First Submitted: May 28, 2009
First Posted: May 29, 2009
Last Update Posted: August 1, 2017
Last Verified: July 2017

Additional relevant MeSH terms:
Breast Neoplasms
Carcinoma in Situ
Breast Carcinoma In Situ
Neoplasms by Site
Neoplasms
Breast Diseases
Skin Diseases
Carcinoma
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type